In addition to the clinical trials mentioned above, a randomized, double-blind, placebo-controlled, phase II interventional study in patients with CKD started in October 2020 to investigate the effect of pirfenidone on kidney fibrosis assessed by diffusion-weighted magnetic resonance imaging and urinary markers of tubulointerstitial fibrosis, as well as eGFR decline and the amount of urinary albumin excretion (NCT04258397) [58]. The gene discussed is ALB; the disease is chronic kidney disease.